Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

FDA-Approved Rolapitant Offers New Option for CINV

September 10th 2015

Marleen Meyers, MD, discusses rolapitant (Varubi), which the FDA recently approved to prevent delayed CINV.

FDA Grants Alectinib Priority Review in NSCLC

September 9th 2015

Alectinib received an FDA priority review designation for patients with ALK-positive, locally advanced or metastatic nonâ€“small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib (Xalkori).

FDA Grants Ixazomib Priority Review in Multiple Myeloma

September 9th 2015

The FDA has granted a priority review designation to the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma.

Overregulation May Delay Access to Life-Prolonging Medications, Increase Costs

September 7th 2015

Overregulation of new drug development has driven up the cost of care and resulted in significant loss of human life by delaying the approval of effective medications.

First US Biosimilar Finally Reaches Market

September 3rd 2015

The first FDA-approved biosimilar, Zarxio, is now available for patients in the United States, following a series of lawsuits and court decisions.

FDA Approves Rolapitant for CINV

September 2nd 2015

The FDA has approved rolapitant (Varubi) for use in combination with other antiemetic agents to prevent delayed CINV.

FDA Grants Elotuzumab Priority Review in Multiple Myeloma

September 1st 2015

The FDA has granted elotuzumab (Empliciti) a priority review for use in combination therapy in pretreated patients with multiple myeloma.

Cabozantinib Granted FDA Breakthrough Designation in Renal Cell Carcinoma

August 24th 2015

Cabozantinib (Cometriq) has received a breakthrough therapy designation from the FDA for the treatment of patients with advanced renal cell carcinoma following one prior therapy.

Frontline Pembrolizumab Receives FDA Priority Review in Melanoma

August 18th 2015

The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma.

FDA Delays Decision on Frontline Nivolumab in Melanoma

August 12th 2015

The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.

CMS Standards for Reporting Call for Advanced Technology, Training

August 8th 2015

Many oncology practices have already made progress in adding appropriate personnel and implementing technology solutions, such as EHR, to enhance their ability to document and report care plans and patient event data. However, to be successful in meeting the specific criteria set forth in the OCM, most existing EHRs will need to be enhanced.

Electronic Health Records Can Increase Malpractice Liability

August 6th 2015

It may be too early to say whether EHRs have increased or decreased liability for physicians as a whole, but some say the technology generally reduces total medical errors and has no effect on insurance rates.

Regulatory Filings Move Dabrafenib/Trametinib Combo Closer to Full Melanoma Approval

July 24th 2015

The FDA has assigned a priority review designation to the combination of dabrafenib and trametinib for patients with unresectable or metastatic BRAFV600 mutation-positive melanoma.

Dabrafenib/Trametinib Combo Receives Breakthrough Designation for NSCLC

July 23rd 2015

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib as a potential treatment for patients with BRAFV600E-mutant non-small cell lung cancer.

Coleman Explains New Biomarker for PARP Inhibitors in Ovarian Cancer

July 17th 2015

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

FDA Extends Cobimetinib Review Period in Advanced Melanoma

July 1st 2015

The FDA has extended the review period for the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib (Zelboraf) for patients with BRAFV600 mutation-positive advanced melanoma by 3 months, making the new decision date November 11, 2015.

OncLive Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program

July 1st 2015

Partnership forms to share the latest news about Sarah Cannon's innovative clinical practices and wide-ranging clinical trial programs for cancer.

Potential Bevacizumab Biomarker Identified in Ovarian Cancer

June 10th 2015

A retrospective analysis of the phase III GOG-0218 trial has identified a potential biomarker of response for bevacizumab in patients with advanced ovarian cancer.

FDA Schedules ODAC Meeting for Necitumumab in NSCLC

June 3rd 2015

The FDA has scheduled an ODAC advisory hearing to discuss the biologics license application for necitumumab in combination with gemcitabine and cisplatin as a first-line treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer.

ASCO Provides Early Look at CancerLinQ Big Data Initiative

June 1st 2015

At the 2015 ASCO Annual Meeting, the much heralded CancerLinQ big data system for helping oncologists more clearly understand treatment patterns and options was offered for demonstration in advance of its rollout.